Acrodermatitis chronica atrophicans

L12_ACRODERMATITIS

acrodermatitis chronica atrophicans: An acrodermatitis characterized by a chronically progressive course, leading to widespread atrophy of the skin. It is a clinical manifestation of Lyme borreliosis.

Suggest a new description

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — L90.4 Hospital discharge: ICD-9 — 7018C Hospital discharge: ICD-8 — 70190 Cause of death: ICD-10 — L90.4 Cause of death: ICD-9 — 7018C Cause of death: ICD-8 — 70190 2 out of 7 registries used, show all original rules.	51
4. Check minimum number of events None	51
5. Include endpoints None	51
6. Filter based on genotype QC (FinnGen only)	51

Control definitions (FinnGen only)

Control exclude: L12_OTHERSKINSUBCUTIS

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: L90
Name in latin: Acrodermatitis chronica atrophicans

NAME	L12_ACRODERMATITIS
CONTROL_EXCLUDE	L12_OTHERSKINSUBCUTIS
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	L904
HD_ICD_9	7018C
HD_ICD_8	70190
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	L904
COD_ICD_9	7018C
COD_ICD_8	70190
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Acrodermatitis chronica atrophicans based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	334	248	84
Only index persons	309	234	75
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.00
Only index persons	0.01	0.01	0.00
Median age at first event (years)
Whole population	62.27	64.11	57.42
Only index persons	62.64	64.30	57.46

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	51	33	18
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	64.19	64.31	63.97

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768443) Skin Pathology biopsy report

9.07

7.88

1.3

1.2

—

(3037522) Nuclear Ab [Titer] in Serum

4.80

6.13

1.3

496.0

805.3

titre

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

8.82

4.57

1.1

1.2

1.1

g/l

—

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

8.82

4.57

1.1

1.2

0.3

0.2

g/l

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

7.06

3.66

1.5

1.2

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

2.93

3.13

1.5

1.2

35.5

40.8

iu/ml

—

(3015736) pH of Urine

171

2.61

2.81

3.6

3.4

—

(42870588) Differential panel, method unspecified - Blood

140

2.54

2.66

7.5

5.2

—

(3039162) Centromere protein B Ab [Units/volume] in Serum

7.75

2.60

1.4

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

4.89

2.57

1.1

1.3

—

(3013707) Erythrocyte sedimentation rate by Westergren method

324

3.08

2.52

5.4

4.5

12.4

11.7

mm/h

0.11

289

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

6.78

2.42

1.0

1.3

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

5.07

2.34

1.3

1.6

—

(40768804) Tissue Pathology biopsy report

174

2.35

2.29

2.6

1.9

—

(3037467) Urinalysis macro (dipstick) panel - Urine

305

2.76

2.20

5.0

4.0

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

4.10

2.00

12.8

7.3

26.5

25.0

mmol/l

—

(3000330) Specific gravity of Urine by Test strip

3.52

1.96

2.7

3.3

—

(3021589) Normoblasts [#/volume] in Blood

192

2.02

1.62

8.1

7.9

0.0

e9/l

0.50

156

(3000494) Fungus identified in Specimen by Culture

2.42

1.58

1.7

1.6

—

(3012095) Magnesium [Moles/volume] in Serum or Plasma

2.22

1.50

2.5

3.2

0.8

mmol/l

0.47

(46235355) HIV 1 and 2 tests - Meaningful Use set

2.22

1.50

1.8

2.0

—

(3002256) Pathology report gross observation

2.45

1.46

1.3

1.1

—

(40758558) Short blood count panel - Blood

109

2.01

1.44

10.8

8.5

—

(3045414) Leukocytes [Presence] in Urine

3.14

1.39

2.0

1.4

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.35

1.38

2.3

2.4

5.3

7.7

umol/l

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

2.10

1.38

1.5

1.2

1.4

14.2

u/ml

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.69

1.34

2.3

1.3

—

(3000991) Gas panel - Venous blood

2.44

1.31

18.6

8.1

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

1.20

0.0

1.8

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

2.66

1.18

8.2

6.6

—

(3027945) Reticulocytes/100 erythrocytes in Blood

2.10

1.10

1.9

3.6

1.8

1.6

—

(40760892) CBC W Ordered Manual Differential panel - Blood

1.87

1.09

3.3

4.7

—

(3026008) Bacteria identified in Urine by Culture

145

1.76

1.09

2.6

2.9

—

(3003458) Phosphate [Moles/volume] in Serum or Plasma

1.93

1.01

8.2

4.0

1.1

mmol/l

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

0.00

1.00

0.0

7.5

—

24.4

—

(3009542) Hematocrit [Volume Fraction] of Blood

388

1.97

0.93

25.0

15.3

39.0

39.8

0.23

262

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.99

0.85

1.7

3.0

—

(3032080) INR in Blood by Coagulation assay

164

1.60

0.82

6.0

8.5

1.2

1.3

inr

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.81

0.0

1.7

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

102

1.67

0.79

4.5

3.3

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.02

0.73

1.4

—

(3018095) Leukocytes [#/volume] in Urine

168

1.54

0.72

3.8

3.4

12.8

52.0

e6/l

1.75

119

(36660697) Celiac disease serology panel - Serum

1.77

0.72

1.1

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

132

1.56

0.70

4.0

2.2

75.8

58.1

u/l

0.53

121

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

179

1.52

0.69

2.2

2.0

111.0

92.3

pmol/l

—

(3014007) Fractional oxyhemoglobin in Arterial blood

1.87

0.68

8.8

9.0

94.0

93.8

—

(36304419) Bacteria [Presence] in Urine

134

1.53

0.65

3.2

2.6

—

(3022145) Colonoscopy Study observation

1.67

0.64

1.9

1.3

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

240

1.48

0.63

8.7

6.3

12.2

11.0

umol/l

0.39

225

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.61

0.0

3.9

—

1.4

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

1.55

0.58

2.5

2.4

0.6

1.1

e6/l

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.65

0.56

1.3

2.0

—

(4035726)

1.61

0.55

1.0

1.2

—

(3007164) IgA [Mass/volume] in Serum or Plasma

1.53

0.55

1.1

1.4

6.3

2.6

g/l

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.59

0.51

3.7

7.6

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.60

0.51

1.9

1.7

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

170

1.40

0.48

3.9

3.0

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

417

1.67

0.48

19.0

13.1

77.8

79.7

ml/min/173m2

0.27

337

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

1.68

0.44

8.8

8.2

0.4

0.7

—

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

1.68

0.44

8.8

8.3

1.3

1.5

—

(3002179) Metamyelocytes/100 leukocytes in Blood

1.62

0.43

1.4

4.1

—

0.3

—

(3042936) Bacteria identified in Isolate by Culture

1.39

0.43

1.9

2.0

—

(3034770) Mitochondria Ab [Titer] in Serum

0.00

0.42

0.0

1.1

—

(3041096) Erythrocytes [Presence] in Urine by Automated

117

1.40

0.41

3.3

3.6

—

(3021440) Promyelocytes/100 leukocytes in Blood

1.47

0.40

1.4

4.2

—

0.0

—

(3025159) Blasts/100 leukocytes in Blood

1.47

0.40

1.4

4.1

—

0.0

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.47

0.40

2.8

2.3

—

(1761868) Lipid panel - Serum or Plasma

143

0.71

0.39

4.0

3.2

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

1.44

0.38

2.6

2.8

6.8

4.0

e6/l

—

(3002173) Hemoglobin [Mass/volume] in Arterial blood

1.48

0.37

9.3

7.5

112.0

121.3

g/l

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.48

0.37

4.2

1.3

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

167

1.33

0.36

4.3

3.8

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.38

0.35

1.8

1.7

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

168

1.31

0.34

2.5

4.1

27.7

25.8

ng/l

0.04

120

(3022217) INR in Platelet poor plasma by Coagulation assay

1.32

0.31

34.0

27.7

—

1.5

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.27

0.29

2.0

1.8

—

(3017181) Myelocytes/100 leukocytes in Blood

1.35

0.24

1.4

4.0

—

0.6

—

(40761535) Cells panel - Urine sediment

1.28

0.23

5.6

4.3

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

112

0.76

0.23

4.6

5.3

2.1

2.3

ug/l

—

(3012544) pH of Venous blood

1.24

0.22

20.8

3.6

—

(4010399)

1.21

0.22

1.2

1.4

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.21

0.0

1.4

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.21

0.0

3.7

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.21

0.0

1.4

—

(3027008) Opiates [Presence] in Urine

0.00

0.21

0.0

1.4

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.6

—

(3016879) Cocaine [Presence] in Urine

0.00

0.21

0.0

1.4

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

3.7

—

86.1

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.21

0.0

3.7

—

(3047181) Lactate [Moles/volume] in Blood

0.00

0.21

0.0

6.3

—

1.0

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

0.00

0.21

0.0

1.4

—

204.7

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3003396) Base excess in Arterial blood by calculation

1.28

0.21

9.2

7.0

0.5

1.7

mmol/l

—

(3027801) Oxygen [Partial pressure] in Arterial blood

1.28

0.21

9.3

7.0

11.9

11.4

kpa

—

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

1.28

0.21

9.5

7.0

5.3

5.0

kpa

—

(3050449) Albumin [Mass/time] in Urine collected for unspecified duration

0.00

0.21

0.0

2.8

—

73.5

—

(4034850)

0.00

0.21

0.0

7.5

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

0.00

0.20

0.0

1.7

—

132.4

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.19

0.19

1.6

1.5

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

101

1.25

0.18

2.3

2.0

—

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

350

1.21

0.17

13.2

7.6

77.2

80.4

u/l

0.18

319

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.18

0.10

2.8

2.4

—

(3019225) pH of Specimen

1.10

0.10

3.6

4.8

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.80

0.08

1.7

1.2

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

0.79

0.08

1.8

1.4

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

431

1.15

0.08

4.7

4.6

4.8

4.6

mmol/l

0.52

400

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

418

1.18

0.07

6.0

6.3

38.1

40.0

mmol/mol

1.10

390

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

418

1.18

0.07

4.3

4.1

1.1

1.3

mmol/l

0.91

380

(3003694) ABO and Rh group [Type] in Blood

120

0.89

0.05

1.5

—

(3044640) Blood type and Crossmatch panel - Blood

130

1.11

0.05

2.6

2.0

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

206

0.95

0.00

3.9

3.5

—

(3023368) Bacteria identified in Blood by Culture

111

0.99

0.00

3.8

3.9

—

(3013512) EKG study

139

1.01

0.00

3.6

4.2

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

241

0.99

0.00

3.2

2.6

—

(3044889) 12 lead EKG panel

303

0.98

0.00

3.8

3.9

—

(3039000) Anion gap in Blood

0.00

0.0

6.0

—

10.3

—

(3041642) Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3038546) Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

0.00

0.0

4.0

—

(3045142) Bone marrow Pathology biopsy report

0.00

0.0

1.0

—

(3024172) Erythropoietin (EPO) [Units/volume] in Serum or Plasma

0.00

0.0

1.1

—

16.5

—

(3022948) Iron [Moles/volume] in Serum or Plasma

0.98

0.00

3.7

2.1

15.2

14.1

umol/l

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

0.91

0.00

4.2

2.1

2.5

2.4

g/l

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

4.2

—

176.9

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.0

1.1

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

0.0

1.0

—

(3005570) Glucose [Moles/volume] in Urine

0.00

0.0

1.6

—

(3018572) Chloride [Moles/volume] in Blood

0.00

0.0

6.0

—

103.0

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.0

1.3

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

3.6

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

0.0

1.0

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

0.0

3.1

—

(36032269) Testosterone Free [Moles/volume] in Serum or Plasma by calculation

0.00

0.0

1.8

—

162.0

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

0.0

3.1

—

3.9

—

(3020717) Zinc [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

12.2

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.0

—

(3051593) INR in Capillary blood by Coagulation assay

0.00

0.0

11.0

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

0.0

1.0

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.0

1.5

—

(42529215) Follitropin [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

2.4

—

5.4

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

0.0

3.1

—

108.4

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.2

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

429

1.01

0.00

4.8

4.7

1.6

1.5

mmol/l

0.49

393

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.0

1.4

—

(40768797) Stomach Pathology biopsy report

0.95

0.00

1.2

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

0.00

0.0

4.2

—

(3044927) Protein electrophoresis panel - Urine

0.00

0.0

1.0

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

440

1.00

0.00

5.1

5.3

2.9

2.7

mmol/l

0.66

407

(3023419) Bacteria identified in Sputum by Culture

0.00

0.0

4.1

—

(21494434) Karyotype in Bone marrow

0.00

0.0

1.0

—

(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3021901) Oxygen saturation in Capillary blood

0.00

0.0

1.6

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

0.00

0.0

1.0

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

0.00

0.0

1.5

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

0.00

0.0

1.3

—

(3040359) Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint L12_ACRODERMATITIS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_ACRODERMATITIS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: L12_ACRODERMATITIS – Acrodermatitis chronica atrophicans

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Acrodermatitis chronica atrophicans

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints